Can a home exercise program help lungs fight interstitial disease?
NCT ID NCT07830602
First seen Sep 21, 2026 · Last updated Sep 21, 2026
Summary
Researchers are testing whether a six-week home-based pulmonary rehabilitation program can improve quality of life and exercise capacity in adults with interstitial lung disease. Participants are randomly assigned to either the home exercise program with weekly phone check-ins or standard care alone. The trial measures changes in a disease-specific quality-of-life questionnaire and a six-minute walk test.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a home-based pulmonary rehabilitation program combining tailored exercise, daily activity diaries, and weekly phone check-ins
- What this could lead to
- If it works, this could give people with interstitial lung disease an exercise program they can follow at home, without traveling to a rehab center.
- What could go wrong
- Home exercise without in-person supervision may be hard to stick with, and the trial is small and limited to one setting in India, so results may not apply everywhere.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age between 18 and 75 years 2. Diagnosis of an ILD by clinician using standard guidelines 3. Having breathlessness graded 1 to 3 on the modified Research Council (mMRC) scale 4. On stable therapy with immunosuppressants or antifibrotics for 3 or more months Exclusion Criteria: 1. Pregnant or lactating women 2. Unwilling to participate in the study 3. Not able to walk or perform upper and lower limb movements 4. Requiring supplemental oxygen
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Interstitial lung diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Post graduate Institute of Medical Education and Research
RECRUITINGChandigarh, Chandigarh, 160012, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Can a JAK inhibitor halt rapid lung decline?
- Could a vibrating platform help people with stiff lungs breathe easier?
- Massive study tracks lung disease progression in 4,000 patients
- New pill aims to halt lung scarring in thousands
- Massive 10-Year study aims to unlock secrets of rare lung disease